Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections

Journal of Infection

Volumn 54, Issue 5, 2007, Pages 463-468

  Lee, Su Young ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Breakpoint; Cefepime; continuous infusion; Extended spectrum Lactamases; Monte Carlo Simulation; Pharmacodynamics; Resistance

Indexed keywords

CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; TOBRAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EXPOSURE; ENTEROBACTER INFECTION; ERADICATION THERAPY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PREDICTION; PROBABILITY; REGRESSION ANALYSIS; STATISTICAL ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CEPHALOSPORINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; TREATMENT OUTCOME;

EID: 34147101777     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.09.004     Document Type: Article

References (21)

1. Thornsberry C., Brown S.D., Yee Y.C., Bouchillon S.K., Marler J.K., and Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother 32 Suppl. B (1993) 31-53
2. Chong Y., Lee K., and Kwon O.H. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli. J Antimicrob Chemother 32 Suppl. B (1993) 21-29
3. Paterson D.L., Ko W.C., Von Gottberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39 (2001) 2206-2212
4. Burgess D.S., Hall R.G., Lewis J.S., Jorgensen J.H., and Patterson J.E. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23 (2003) 1232-1237
5. Thomson K.S., and Moland E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 45 (2001) 3548-3554
6. Szabo D., Mathe A., Filetoth Z., Anderlik P., Rokusz L., and Rozgonyi F. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 45 (2001) 1287-1291
7. Maglio D., Ong C., Banevicius M.A., Geng Q., Nightingale C.H., and Nicolau D.P. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 48 (2004) 1941-1947
8. Andes D., and Craig W. Impact of extended-spectrum beta-lactamase (ESBL) production on the activity of cefepime in a murine-thigh infection model. [abstract A1099]. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Illinois) (2001), American Society for Microbiology, Chicago 26
9. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22 (1995) 89-96
10. Tam V.H., McKinnon P.S., Akins R.L., Rybak M.J., and Drusano G.L. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50 (2002) 425-428
11. Mouton J.W., and Vinks A.A. Is continuous infusion of beta-lactam antibiotics worthwhile? -efficacy and pharmacokinetic considerations. J Antimicrob Chemother 38 (1996) 5-15
12. Kotapati S., Kuti J.L., Nightingale C.H., and Nicolau D.P. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 51 (2005) 211-217
13. Davis G.A., and Chandler M.H. Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 53 (1996) 1028-1032
14. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
15. CLSI. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Fifteenth ed. 25 vol (2005), Clinical and Laboratory Standards Institute, Wayne, Pennsylvania
16. Dandekar P.K., Tetreault J., Quinn J.P., Nightingale C.H., and Nicolau D.P. Prevalence of extended spectrum β-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut. Diagn Microbiol Infect Dis 49 (2004) 37-39
17. Tam V.H., McKinnon P.S., Akins R.L., Drusano G.L., and Rybak M.J. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 47 (2003) 1853-1861
18. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48 (2004) 4574-4581
19. Craig W.A., Bhavnani S.M., Ambrose P.G., Dudley M.N., and Jones R.N. Evaluation of clinical outcome among patients with ESBL-producing Enterobacteriaceae treated with cephalosporin monotherapy. [abstract K-129]. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (December 16-19; 2005), American Society for Microbiology, Washington DC
20. Zanetti G., Bally F., Greub G., Garbino J., Kinge T., Lew D., et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47 (2003) 3442-3447
21. Tam V.H., Louie A., Lomaestro B.M., and Drusano G.L. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 23 (2003) 291-295